Nuvig Therapeutics, Inc.

It looks as though Sanofi and Regeneron’s Dupixent will be the first approved treatment for bullous pemphigoid (BP) and have the market to itself for years given that closest rival Argenx has pulled t

It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th